drugset / Trial / NCT02971982
PCD Versus RCD for the Treatment of Patients With Waldenstrom's Macroglobulinemia
RandomizedParallel-groupOpen-labelTreatment
Summary
Patients will receive RCD or PCD combination as induction treatment followed by rituximab or velcade maintenance therapy, as the investigators try to compare the, very good partial remission (VGPR) rate, complete remission (CR) rates, Overall remission rate (MR+CR + VGPR + partial remission (PR) rate), major reaction rate (MRR, PR+VGPR+CR) at the end of the research.
Timeline
- Start
- 2016-10
- Primary completion
- 2018-10
- Completion
- 2018-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bortezomib | Small molecule | 1.3 mg/m2 | — |
| Subject | Dexamethasone | Small molecule | 10 mg | — |
| Subject | Dexamethasone | Small molecule | 20 mg | — |
| Subject | Rituximab | Monoclonal antibody | 375 mg/m2 | — |
| Background | Cyclophosphamide | Other / unclassified | 750 mg | — |
Indications
No indication recorded.